Anti|TNF therapy and immunogenicity in inflammatory bowel diseases

Anti-TNF therapy and immunogenicity in inflammatory bowel diseases

The purpose of this review is to determine what are the main mechanisms involved in IBD; to assess the recommended treatments; to explore the mechanisms of ...

Anti-TNF therapy and immunogenicity in inflammatory bowel diseases

Inflammatory bowel diseases are chronic illnesses that involve intestinal inflammation and are usually diagnosed as Crohn's disease or ...

Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and ...

Tumor necrosis factor inhibitors (anti-TNF) are effective therapies for several immune-mediated inflammatory diseases (IMIDs).

Overcoming Immunogenicity to Anti-TNF Therapy by Reactively ...

Similar results were seen in a prospective randomized controlled trial; patients with IBD with immunogenic failure to the first anti-TNF given ...

Immunogenicity and Loss of Effectiveness of Biologic Therapy for ...

Many patients with inflammatory bowel disease (IBD) experience a loss of effectiveness to biologic therapy (i.e., anti-TNF therapy, etc.).

Report of the ECCO pathogenesis workshop on anti-TNF therapy ...

tumor necrosis factors; crohn's disease; inflammatory bowel disease; ulcerative colitis; drug clearance; monoclonal antibodies; pharmacokinetics ...

HLA-DQA1*05 ASSOCIATES WITH IMMUNOGENICITY AND LOSS ...

HLA-DQA1*05 ASSOCIATES WITH IMMUNOGENICITY AND LOSS OF RESPONSE TO ANTI-TNF THERAPY IN THE IBD POPULATION: A META-ANALYSIS · Article contents ...

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis ...

We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with inflammatory bowel disease (IBD)

3-year data from the prospective, multicentre PANTS cohort study

To our knowledge, the PANTS-extension study is the largest and longest prospective study of anti-TNF therapy in IBD to date. Patients were ...

Predictive biomarkers for anti-TNF alpha therapy in IBD patients

While various treatments have demonstrated efficacy in adult IBD patients, the advent of anti-TNF therapies has significantly revolutionized ...

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist ...

Introduction: Tumor necrosis factor antagonists (anti-TNF) therapies are used for the management of moderate to severe inflammatory bowel ...

S863 Impact of Race on ANTI-TNF Immunogenicity in Patients...

Immunogenicity is a major contributor to anti-tumor necrosis factor (anti-TNF) treatment failure in inflammatory bowel disease (IBD). Immunomodulator and ...

Risk of consecutive immunogenic failure in switchers of anti-tumor ...

Evidence regarding the risk of immunogenicity in patients with inflammatory bowel disease (IBD) who switched anti-tumor necrosis factor ...

Withdrawal of Immunomodulators or TNF Antagonists in Patients ...

Withdrawal of immunomodulators (IMMs) or tumor necrosis factor (TNF) antagonists in patients with inflammatory bowel diseases (IBDs) in ...

Immunogenicity of biologics in inflammatory bowel disease

Biologic therapies carry an intrinsic risk of immunogenicity, although reported rates of ADAbs vary considerably.

Optimizing anti-TNF treatment in inflammatory bowel disease

Infliximab, the chimeric monoclonal immunoglobulin (Ig)G1 antibody to tumor necrosis factor (TNF) has changed our therapy of Crohn's disease.

Hype or Reality in 2020? Can We Predict Response to Anti-TNF?

The advent of anti-TNF agents as the first approved targeted therapy in the treatment of inflammatory bowel disease (IBD) patients has made a major impact on ...

Anti-TNF therapy and immunogenicity in inflammatory bowel diseases

The advent of monoclonal antibodies (anti-tumor necrosis factor, anti-integrin, anti-interleukin − 23) has revolutionized IBD management. Nevertheless, these ...

immunogenicity is not the root cause for loss of response to anti ...

Although the therapeutic armamentarium of inflammatory bowel disease (IBD) has been expanding in recent years, anti-tumour necrosis factor (anti ...

Immunogenicity of biologics in inflammatory bowel disease

Assessment of the immunogenicity of biologic therapies and their clinical implications for Crohn's disease and ulcerative colitis finds that further ...